Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.
Barzolvolimab improved UAS7 from baseline to week 12 in antihistamine-refractory chronic spontaneous urticaria, with the largest mean change at 300 mg every 8 weeks (-13.41).